Press Releases

Debiopharm further explores the potential of its potent, highly selective WEE1 inhibitor Debio 0123 in phase 1 cancer study

Grand gagnant du 6eme Challenge 2021 pour la qualité de vie du patient, le projet WheelyWasher permet de nettoyer automatiquement…

Swiss-based Debiopharm co-invests in the future of cell therapies on a chip through the latest $25 million Series A round…

CARB-X Funds The 3rd Round of Debiopharm’s Targeted Antibiotic Program To Combat Resistant N. Gonorrhoeae Infections

Debiopharm & Dexa Medica Launch Triptorelin Collaboration to Bring New Hope To Women With Endometriosis

Debiopharm Encourages Breakthough Cancer Research In Japan Through its Competitive JCA Mauvernay Award

6e Challenge Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale

Debiopharm and Ubix Therapeutics launch research to develop a new anti-cancer modality – antibody degraducer® conjugates

Debiopharm’s CD37 antibody drug conjugate shows promising phase II results for the treatment of B-cell malignancies